DOCSLIB.ORG

Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: a Real-World Study from China

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: a Real-World Study from China Cancer Management and Research Dovepress open access to scientific and medical research Open Access Full Text Article ORIGINAL RESEARCH Large Scale, Multicenter, Prospective Study of Apatinib in Advanced Gastric Cancer: A Real-World Study from China This article was published in the following Dove Press journal: Cancer Management and Research 1, 2, 3, Wanren Peng, * Fenglin Zhang, * Zishu Wang, * Background: In China, gastric cancer (GC) ranks second in incidence and mortality. Over Dongliang Li, 4,*YifuHe,5,* Zhongliang Ning,6 Lili Sheng,7 Jidong Wang,8 Xiaoyang Xia,9 80% of patients with GC were diagnosed at an advanced stage with poor clinical outcome. Changjun Yu,10 Zian Wang,3 Yo n g Z h ao, 11 12 13 14 Chemotherapy was the mainstream treatment with limited benefit. Apatinib, an inhibitor of Hui Liang, Bing Hu, Cuiling Sun, Daoqin Wang,15 Yunsheng Cheng,16 Ming Pan,17 targeting vascular endothelial growth factor receptor 2 (VEGFR2), has been approved for Liming Xia,18 Xinglai Guo,19 Yanshun Zhang,20 Zhiqiang Hu,21 Xinzhong Li,22 Lin Lu,23 Jun Zhang,24 third-line treatment of advanced gastric cancer. However, the data of apatinib treatment in the Hong Qian,8 Hua Xie,25 Guoping Sun1,* real-world setting are limited. In this real-world study, we aimed to understand the current 1Department of Oncology, The First Affiliated Hospital of treatment pattern of apatinib, investigate the effectiveness and safety of apatinib in real-world Anhui Medical University, Hefei, Anhui 230022, People’s Republic of China; 2Department of Oncology, People’s settings, and explore the potential factors associated with the clinical outcomes. Hospital of Maanshan City, Maanshan, Anhui 243000, People’s Republic of China; 3Department of Oncology, The Methods: This was a prospective, multicenter observational study in a real-world setting. First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui 233004, People’sRepublicofChina;4Department of Patients aged ≥18 years with histologic diagnosis of advanced GC were eligible for enroll- Gastrointestinal Surgery, People’sHospitalofLu’an City, Lu’an, Anhui 237005, People’s Republic of China; ment. The eligible patients received either apatinib monotherapy or apatinib plus chemother- 5Department of Oncology, The First Affiliated Hospital of University of Science and Technology of China (Anhui apy by physician’s discretion. Apatinib treatment could be used as first-line, second-line, or Provincial Cancer Hospital), Hefei, Anhui 230022, People’s Republic of China; 6Department of Gastrointestinal third-line and above therapy. The primary endpoint was progression-free survival (PFS). The Surgery, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer secondary endpoints were overall survival (OS), ORR, DCR, and safety profile. Hospital), Hefei, Anhui 230022, People’s Republic of China; 7Department of Oncology, Yijishan Hospital of WanNan Results: A total of 737 patients with advanced gastric cancer treated with apatinib were Medical College, Wuhu, Anhui 340202, People’sRepublicof China; 8Department of Oncology, The Navy Anqing included in the FAS population. A total of 54.9% patients used apatinib monotherapy and Hospital, Anqing, Anhui 246003, People’sRepublicofChina; 9Department of Oncology, The First People’sHospitalof 45.1% patients used apatinib combination therapy. A total of 44.1% patients received Chuzhou City, Chuzhou, Anhui 239000, People’sRepublic of China; 10Department of Gastrointestinal Surgery, The apatinib in first-line treatment, 28.2% in second-line, and 27.7% in third-line and above. In First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, People’s Republic of China; 11Department of first-line treatment, the objective response rate (ORR) was 9.09% and 16.42% in apatinib Oncology, People’s Hospital of Lu’an City, Lu’an, Anhui 237005, People’s Republic of China; 12Department of monotherapy and combination therapy groups, and disease control rate (DCR) was 78.41% Oncology, Lu’an Hospital of Traditional Chinese Medicine, Lu’an, Anhui 237006, People’s Republic of China; and 89.29%, respectively. Patients who received combination therapy achieved significantly 13Department of Oncology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui longer median progression-free survival (mPFS; 6.18 vs 3.52 months, p<0.01) and median 230022, People’s Republic of China; 14Department of Oncology, People’s Hospital of Fuyang City, Fuyang, Anhui overall survival (mOS; 8.72 vs 5.92 months, p<0.01) compared with monotherapy. In 236047, People’s Republic of China; 15Department of Gastrointestinal Surgery, Wanbei Coal-Electricity Group second-line and third-line therapy, combination therapy showed a better trend in tumor General Hospital, Suzhou, Anhui 234000, People’sRepublic of China; 16Department of Oncology, The Second Affiliated response and survival outcomes compared with monotherapy. For all patients, apatinib Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of China; 17Department of Oncology, combined with paclitaxel were associated with longer mPFS compared with other combina- People’s Hospital of Chizhou City, Chizhou, Anhui 247000, People’s Republic of China; 18Department of Oncology,The tions (8.88 vs 6.62 months). Multivariate analysis showed that combination with paclitaxel First Affiliated Hospital of Anhui University of Chinese Medicine, Hefei, Anhui 230031, People’sRepublicofChina; (p=0.02) and experience of apatinib-related specific AEs (p<0.01) were independent pre- 19Department of Oncology, Fuyang Cancer Hospital, Fuyang, Anhui 236033, People’s Republic of China; dictors for PFS and OS. The safety profile was tolerable and no unexpected adverse events 20Department of Oncology, Huainan First People’s Hospital, Huainan, Anhui 232000, People’sRepublicof were reported. China; 21Department of Oncology, Huaibei Miners General Hospital, Huaibei, Anhui 235000, People’s Republic of China; 22Department of Oncology, People’s Hospital of Conclusion: In a real-world setting, apatinib showed a favorable effectiveness and safety Huaibei, Huaibei, Anhui 235000, People’s Republic of China; fi 23Department of Oncology, The 901 Hospital of the Joint pro le in patients with advanced gastric cancer. Apatinib combination therapy, especially Logistic Support Force of the People’s Liberation Army of fi fi China, Hefei, Anhui 230033, People’s Republic of China; combined with paclitaxel, might lead to better survival bene tin rst-line treatment. 24Department of Oncology, The Second People’s Hospital fi of Wuhu, Wuhu, Anhui 241001, People’s Republic of China; Combination with paclitaxel and the occurrence of apatinib-speci c AEs were independent 25Department of Oncology, The People’sHospitalof Xuancheng City, Xuancheng, Anhui 242000, People’s factors associated with better survival outcomes. Republic of China Trial Registration: NCT03333967. *These authors contributed equally to this work Keywords: apatinib, combination therapy, real-world, advanced gastric cancer Correspondence: Guoping Sun Email [email protected] submit your manuscript | www.dovepress.com Cancer Management and Research 2020:12 6977–6985 6977 DovePress © 2020 Peng et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php – http://doi.org/10.2147/CMAR.S249153 and incorporate the Creative Commons Attribution Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). Peng et al Dovepress Introduction contraindication for apatinib, they were not enrolled in Gastric cancer (GC) is one of the most common malignant the current study. In addition, the patients who were not tumors and the third leading cause of cancer-related deaths eligible for this study according to the physician’s discre- worldwide.1 In China, GC ranks second in incidence and tion were not enrolled in this study. mortality.2–5 Over 80% of patients with GC are diagnosed at an advanced stage with poor clinical outcome and a low Study Design and Treatment 5-year survival rate of <20%.6,7 Chemotherapy is the This was a prospective, multicenter observational study in recommended treatment in China but the benefits are lim- a real-world setting. The eligible patients received apatinib ited. Consequently, it is crucial to explore and optimize monotherapy or apatinib plus chemotherapy. The che- treatment strategy to improve the survival benefitof motherapy regimens included docetaxel, paclitaxel, cape- fl patients with GC. citabine and oxaliplatin (XELOX), 5- uorouracil (5-Fu), In recent years, anti-angiogenic therapy has become a epirubicin+oxaliplatin+capecitabine (EOX), docetaxel fl ’ main treatment choice for cancer patients, and some angio- +cisplatin+ uorouracil (DCF). Based on physician s dis- ’ genesis inhibitors have shown favorable efficacy in lung, cretion and patients approval, apatinib could be used as fi breast, colon and gastric cancers.8,9 Apatinib is a small- rst-line, second-line, or third-line and above therapy. molecule tyrosine kinase inhibitor (TKI) that highly selec- Apatinib was administered (250
Load more

Recommended publications
  • SUBSTR DESCR International Schools CAMEROON 000944
    SUBSTR DESCR International Schools CAMEROON 000944 Universite Yaounde CANADA 001048 Athabasca University 005528 Augustana University College 005516 Bishops University 005525 Concordia Lutheran College 002464 Keyano College 005536 Lethbridge Comm Coll 005536 Lethbridge Community College 002466 Prairie Bible College 009294 Red Deer College 005464 Southern Alberta Inst Tech 005464 Southrn Alb Inst Tec 005464 Southrn Alberta Inst Tech 005567 Univ Alberta 005435 Univ Alberta Calgary Branch 005435 Univ Calgary 005567 University Of Alberta 005469 University Of Lethbridge 003535 Capilano College 008792 Northern Lights Community Coll 006220 Northwest Cmty Coll 002313 Okanagan College 001054 Royal Roads Military Col 002193 Selkirk Col Castlegar Campus 002194 Selkirk Col Rosemont Campus 002195 Selkirk Col Trail Campus 005454 Selkirk College 005597 Simon Fraser University 005569 University Of British Columbia 005590 University Of Victoria 006310 Vancouver Comm College 005515 Brandon University 007078 Sal Army C Booth Bib 001058 United Col Winnipeg 005575 Univ Manitoba 001058 Univ Winnipeg 001058 Wesley Col Winnipeg 005545 Mount Allison University 001051 Universite De Moncton 005578 University Of New Brunswick 005497 Memorial Univ Newfou 005511 Acadia University 005524 Dalhousie University 005478 Mount St Vincent University 005459 Nova Scotia Agricultural Coll 001052 Nova Scotia Col Art Design 005557 St Francis Xavier University 005562 St Marys University International Schools 001057 Tech Univ Nova Scotia 001049 Univ Col Cape Breton 001055 Universite
    [Show full text]
  • Final Program of CCC2020
    第三十九届中国控制会议 The 39th Chinese Control Conference 程序册 Final Program 主办单位 中国自动化学会控制理论专业委员会 中国自动化学会 中国系统工程学会 承办单位 东北大学 CCC2020 Sponsoring Organizations Technical Committee on Control Theory, Chinese Association of Automation Chinese Association of Automation Systems Engineering Society of China Northeastern University, China 2020 年 7 月 27-29 日，中国·沈阳 July 27-29, 2020, Shenyang, China Proceedings of CCC2020 IEEE Catalog Number: CFP2040A -USB ISBN: 978-988-15639-9-6 CCC2020 Copyright and Reprint Permission: This material is permitted for personal use. For any other copying, reprint, republication or redistribution permission, please contact TCCT Secretariat, No. 55 Zhongguancun East Road, Beijing 100190, P. R. China. All rights reserved. Copyright@2020 by TCCT. 目录 (Contents) 目录 (Contents) ................................................................................................................................................... i 欢迎辞 (Welcome Address) ................................................................................................................................1 组织机构 (Conference Committees) ...................................................................................................................4 重要信息 (Important Information) ....................................................................................................................11 口头报告与张贴报告要求 (Instruction for Oral and Poster Presentations) .....................................................12 大会报告 (Plenary Lectures).............................................................................................................................14
    [Show full text]
  • February 2014
    winter issue february 2014 News from the Ohio Articulation & Transfer Network IN THIS ISSUE Special Features Special Features. 1-4 Board of Regents welcomes delegates from Anhui, China Policy & Compliance In October, Chancellor John Carey hosted several university delegates from Anhui, Reports. 4 China for a visit to the Ohio Board of Regents (OBR) offices. Anhui, China has been a sister city to Columbus since 1988 when a group from Columbus traveled Meetings of the Minds. 5 to China to negotiate obtaining a panda bear for the Columbus Zoo. Transfer Technology. 6-7 Delegates were present from Anhui University, Bengbu Medical College, (CT)2 Corner. 7-8 Chuzhou University, Fuyang University, Hefei University, Huaibei Normal College, Staff Happenings. 9 Huangshan College, and Wannan College. Delegates were provided a brief overview of Ohio’s public higher education system by Ohio Board of Regents (OBR) staff members Paula Compton, Charles See, A Note from Paula Jeff Robinson, David Cannon, and Shane DeGarmo. Chancellor Carey responded Even though it has been a long, to questions from the delgates on cold winter, the OATN staff are topics such as supporting STEM faculty keeping warm with the constant and initiatives in Ohio public institutions of higher transfer activities happening education, the Choose Ohio First scholarship, and funding Ohio public higher around the state. We continue education. to be so grateful for our many colleagues around the state The event was arranged by Paula Compton and Lin Ba, with help from the OATN (and beyond with some of staff. Lin Ba is a professor of economics at The Ohio State University’s Newark our long-reaching initiatives) campus.
    [Show full text]
  • Text Mining and Predicting Disease-Gene-Drug Associations of Hypertension Data Cubes-Based
    Text Mining and Predicting Disease-Gene-Drug Associations of Hypertension Data Cubes-Based Xing Wei Bengbu Medical College Xuelian Chang ( [email protected] ) Bengbu Medical College https://orcid.org/0000-0003-4974-2585 Yanqiu Wang Aliated Hospital of Bengbu Medical College Jing Xie Bengbu Medical College Xiaodi Yang Bengbu Medical College Xiulin Jiang Bengbu Medical College Research Keywords: Text mining, Hypertension, Data cube, Association extraction, Association Prediction Posted Date: April 20th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-22783/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/23 Abstract Background Predispositions to hypertension is possibly associated with numerous potential gene polymorphisms and systemic disorders. Large-scale text mining of biomedical literature is a exible and essential tool that can be applied to search for innovative drugs and treatments for diseases, such as investigating and predicting the bio-entities associations. Result We proposed a generality approach for extracting and predicting hypertension-related disease- gene-drug associations based on dictionary and data cube from biomedical abstracts. After data preprocessing, we constructed the 0-D vertex cube, which we then ltered to construct three 1-D cubes consisting of 252 diseases, 185 genes, and 141 drugs. By applying association rules to quantify the disease-gene-drug associations, we found 235 associations between 79 diseases and the 71 genes, and AUCs was 84.1%; 196 associations between 43 diseases and 102 drugs, and AUCs was 85.8%; 160 associations between 31 genes and 106 drugs, and AUCs was 83.6%.
    [Show full text]
  • A Complete Collection of Chinese Institutes and Universities For
    Study in China——All China Universities All China Universities 2019.12 Please download WeChat app and follow our official account (scan QR code below or add WeChat ID: A15810086985), to start your application journey. Study in China——All China Universities Anhui 安徽 【www.studyinanhui.com】 1. Anhui University 安徽大学 http://ahu.admissions.cn 2. University of Science and Technology of China 中国科学技术大学 http://ustc.admissions.cn 3. Hefei University of Technology 合肥工业大学 http://hfut.admissions.cn 4. Anhui University of Technology 安徽工业大学 http://ahut.admissions.cn 5. Anhui University of Science and Technology 安徽理工大学 http://aust.admissions.cn 6. Anhui Engineering University 安徽工程大学 http://ahpu.admissions.cn 7. Anhui Agricultural University 安徽农业大学 http://ahau.admissions.cn 8. Anhui Medical University 安徽医科大学 http://ahmu.admissions.cn 9. Bengbu Medical College 蚌埠医学院 http://bbmc.admissions.cn 10. Wannan Medical College 皖南医学院 http://wnmc.admissions.cn 11. Anhui University of Chinese Medicine 安徽中医药大学 http://ahtcm.admissions.cn 12. Anhui Normal University 安徽师范大学 http://ahnu.admissions.cn 13. Fuyang Normal University 阜阳师范大学 http://fynu.admissions.cn 14. Anqing Teachers College 安庆师范大学 http://aqtc.admissions.cn 15. Huaibei Normal University 淮北师范大学 http://chnu.admissions.cn Please download WeChat app and follow our official account (scan QR code below or add WeChat ID: A15810086985), to start your application journey. Study in China——All China Universities 16. Huangshan University 黄山学院 http://hsu.admissions.cn 17. Western Anhui University 皖西学院 http://wxc.admissions.cn 18. Chuzhou University 滁州学院 http://chzu.admissions.cn 19. Anhui University of Finance & Economics 安徽财经大学 http://aufe.admissions.cn 20. Suzhou University 宿州学院 http://ahszu.admissions.cn 21.
    [Show full text]
  • Chen Guang Yu, MD, Ph.D. CONTENT
    CURRICULUM VITAE ~ Chen Guang Yu, M.D., Ph.D. CONTENT ORGANIZATION I. GENERAL INFORMATION II. ACADEMIC APPOINTMENTS III. EDUCATION IV. PROFESSIONAL EXPERIENCES V. HOSPITAL or CLINICAL APPOINTMENTS VI. CONSULTING ACTIVITIES VII. TEACHING ACTIVITIES VIII. ADVISING ACTIVITIES IX. HONORS & AWARDS X. PROFESSIONAL ACTIVITIES, PUBLIC SERVICE & PROFESSIONAL DEVELOPMENT XI. SPEAKING ENGAGEMENTS XII. RESEARCH & INTELLECTUAL CONTRIBUTIONS Date Prepared: 11/01/2016 CURRICULUM VITAE I. GENERAL INFORMATION Citizenship: USA Gender: Male Residence: 360 Hays Blvd Lexington, KY 40509 Email: [email protected] Phone: 859-556-9558 II. ACADEMIC APPOINTMENTS 01/2017-present Research Assistant Professor at Spinal Cord and Brain Injury Research Center, Department of Neuroscience, University of Kentucky College of Medicine, 741 S Limestone St., Office: B455 BBSRB, Lexington, KY 40536 05/2016-11/2016 Chief Scientist, RNA Nanotechnology Transfer Project, Matt Holding Pharmaceutical LLC at Rev1 Ventures, 1275 Kinnear Rd, Ohio State University SciTech (Office) and 1381 Kinnear Rd, Ohio State University Nanotech West Lab (Laboratory), Columbus OH 43212 01/2008-05/2016 Research Assistant Professor/Principal Investigator at Spinal Cord and Brain Injury Research Center, Department of Anatomy and Neurobiology, University of Kentucky College of Medicine, 741 S Limestone St., B465 BBSRB, Lexington, KY 40536 05/2005-12/2007 Research Scientist III in Dr. James Geddes’s laboratory at Spinal Cord and Brain Injury Research Center, Department of Anatomy and Neurobiology University
    [Show full text]
  • University of Leeds Chinese Accepted Institution List 2021
    University of Leeds Chinese accepted Institution List 2021 This list applies to courses in: All Engineering and Computing courses School of Mathematics School of Education School of Politics and International Studies School of Sociology and Social Policy GPA Requirements 2:1 = 75-85% 2:2 = 70-80% Please visit https://courses.leeds.ac.uk to find out which courses require a 2:1 and a 2:2. Please note: This document is to be used as a guide only. Final decisions will be made by the University of Leeds admissions teams.
    [Show full text]
  • Prevalence of Sleep Disturbances and Sleep Quality in Chinese Healthcare Workers During the COVID-19 Pandemic: a Systematic Review and Meta-Analysis
    SYSTEMATIC REVIEW published: 18 February 2021 doi: 10.3389/fpsyt.2021.646342 Prevalence of Sleep Disturbances and Sleep Quality in Chinese Healthcare Workers During the COVID-19 Pandemic: A Systematic Review and Meta-Analysis Lei Xia 1†, Changhao Chen 2†, Zhiqiang Liu 3†, Xiangfen Luo 1,4, Chunyan Guo 3, Zhiwei Liu 5, Kai Zhang 1* and Huanzhong Liu 1* Edited by: 1 2 Yanhui Liao, Department of Psychiatry, Chaohu Hospital of Anhui Medical University, Hefei, China, Department of Psychiatry, Suzhou 3 Sir Run Run Shaw Hospital, China Second People’s Hospital, Suzhou, China, Department of General Medicine, Chaohu Hospital of Anhui Medical University, Hefei, China, 4 Department of Psychiatry, The Second Affiliated Hospital of Bengbu Medical College, Bengbu, China, Reviewed by: 5 Department of Psychiatry, Fuyang Third People’s Hospital, Fuyang, China Wei Zheng, Guangzhou Medical University, China Shi-Bin Wang, Objectives: Healthcare workers (HWs) experienced high levels of work stress during the Guangdong Mental Health COVID-19 pandemic, leading to a high risk of sleep disturbances. This meta-analysis Center, China Yu-Tao Xiang, aimed to explore the prevalence of sleep disturbances and sleep quality in Chinese HWs University of Macau, China during the COVID-19 pandemic. *Correspondence: Kai Zhang Methods: English (PubMed, EMBASE, PsycINFO, Web of Science, and the Cochrane [email protected] Library) and Chinese databases (WanFang, Chinese National Knowledge Infrastructure, Huanzhong Liu and SinoMed) were systematically and independently searched for relevant studies [email protected] published from December 1, 2019, to May 20, 2020. The pooled prevalence of sleep † These authors have contributed disturbances and sleep quality were calculated using a random-effects model.
    [Show full text]
  • Real-Time in Situ Navigation System with Indocyanine Green Fluorescence for Sentinel Lymph Node Biopsy in Patients with Breast Cancer
    Real-time in Situ Navigation System with Indocyanine Green Fluorescence for Sentinel Lymph Node Biopsy in Patients with Breast Cancer Zhaorui Wang The rst aliated hospital of Anhui meidical University,Department of Breast Surgery Xiaowei Yang The rst aliated Hospital of Anhui Medical University,Department of Breast Surgery Peng Liu University of Science and Technology Chunguang Han The rst Aliated Hosptal of Anhui medical university,Department of Breast Surgery Yubo Pan The rst Aliated Hospital of Anhui Medical Universiy, Department of Breast Surgery Jing Pei ( [email protected] ) The rst Aliated Hospital of Anhui Medical University Research Keywords: breast cancer, sentinel lymph node biopsy, indocyanine green, real-time in situ navigation Posted Date: September 14th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-70840/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Version of Record: A version of this preprint was published at Frontiers in Oncology on May 5th, 2021. See the published version at https://doi.org/10.3389/fonc.2021.621914. Page 1/14 Abstract Background: The naked-eye invisibility of indocyanine green uorescence limits the application of near- infrared uorescence imaging (NIR) systems for real-time navigation during sentinel lymph node biopsy (SLNB) in patients with breast cancer undergoing surgery. This study aims to evaluate the effectiveness and safety of a novel NIR system in visualizing indocyanine green uorescence images in the surgical eld and the application value of combined methylene blue (MB) and the novel NIR system in SLNB. Methods: Sixty patients with clinical node-negative breast cancer received indocyanine green (ICG) and MB as tracers.
    [Show full text]
  • 1 Please Read These Instructions Carefully
    PLEASE READ THESE INSTRUCTIONS CAREFULLY. MISTAKES IN YOUR CSC APPLICATION COULD LEAD TO YOUR APPLICATION BEING REJECTED. Visit http://studyinchina.csc.edu.cn/#/login to CREATE AN ACCOUNT. • The online application works best with Firefox or Internet Explorer (11.0). Menu selection functions may not work with other browsers. • The online application is only available in Chinese and English. 1 • Please read this page carefully before clicking on the “Application online” tab to start your application. 2 • The Program Category is Type B. • The Agency No. matches the university you will be attending. See Appendix A for a list of the Chinese university agency numbers. • Use the + by each section to expand on that section of the form. 3 • Fill out your personal information accurately. o Make sure to have a valid passport at the time of your application. o Use the name and date of birth that are on your passport. Use the name on your passport for all correspondences with the CLIC office or Chinese institutions. o List Canadian as your Nationality, even if you have dual citizenship. Only Canadian citizens are eligible for CLIC support. o Enter the mailing address for where you want your admission documents to be sent under Permanent Address. Leave Current Address blank. Contact your home or host university coordinator to find out when you will receive your admission documents. Contact information for you home university CLIC liaison can be found here: http://clicstudyinchina.com/contact-us/ 4 • Fill out your Education and Employment History accurately. o For Highest Education enter your current degree studies.
    [Show full text]
  • CONICYT Ranking Por Disciplina > Sub-Área OECD (Académicas) Comisión Nacional De Investigación 1
    CONICYT Ranking por Disciplina > Sub-área OECD (Académicas) Comisión Nacional de Investigación 1. Ciencias Naturales > 1.3 Ciencias Físicas y Astronomía Científica y Tecnológica PAÍS INSTITUCIÓN RANKING PUNTAJE FRANCE Universite Paris Saclay (ComUE) 1 5,000 USA University of California Berkeley 2 5,000 USA California Institute of Technology 3 5,000 USA Massachusetts Institute of Technology (MIT) 4 5,000 USA Harvard University 5 5,000 USA Stanford University 6 5,000 UNITED KINGDOM University of Cambridge 7 5,000 FRANCE Sorbonne Universite 8 5,000 USA University of Chicago 9 5,000 JAPAN University of Tokyo 10 5,000 UNITED KINGDOM University of Oxford 11 5,000 FRANCE Universite Sorbonne Paris Cite-USPC (ComUE) 12 5,000 FRANCE University of Paris Diderot 13 5,000 FRANCE PSL Research University Paris (ComUE) 14 5,000 USA Princeton University 15 5,000 FRANCE Universite Paris Sud - Paris XI 16 5,000 CHINA Tsinghua University 17 5,000 USA University of Maryland College Park 18 5,000 UNITED KINGDOM University College London 19 5,000 UNITED KINGDOM Imperial College London 20 5,000 FRANCE Communaute Universite Grenoble Alpes 21 5,000 USA University of Michigan 22 5,000 CANADA University of Toronto 23 5,000 FRANCE Universite Grenoble Alpes (UGA) 24 5,000 ITALY Sapienza University Rome 25 5,000 ITALY University of Padua 26 5,000 CHINA Peking University 27 5,000 UNITED KINGDOM University of Edinburgh 28 5,000 USA University of Illinois Urbana-Champaign 29 5,000 USA Columbia University 30 5,000 INDIA Indian Institute of Technology System (IIT System)
    [Show full text]
  • FORMATO PDF Ranking Instituciones Acadã©Micas Por Sub áRea OCDE
    Ranking Instituciones Académicas por sub área OCDE 2020 1. Cs. Naturales > 1.02 Computación y Ciencias de la Informática PAÍS INSTITUCIÓN RANKING PUNTAJE CHINA Tsinghua University 1 5,000 USA Carnegie Mellon University 2 5,000 USA University of California Berkeley 3 5,000 USA Stanford University 4 5,000 USA Massachusetts Institute of Technology (MIT) 5 5,000 SINGAPORE Nanyang Technological University & National Institute of Education (NIE) Singapore 6 5,000 SWITZERLAND ETH Zurich 7 5,000 USA University of Michigan 8 5,000 HONG KONG Chinese University of Hong Kong 9 5,000 SINGAPORE National University of Singapore 10 5,000 CHINA Shanghai Jiao Tong University 11 5,000 FRANCE Universite Cote d'Azur (ComUE) 12 5,000 UNITED KINGDOM University of Oxford 13 5,000 USA University of Illinois Urbana-Champaign 14 5,000 CHINA Harbin Institute of Technology 15 5,000 CHINA Peking University 16 5,000 USA University of Washington Seattle 17 5,000 USA Georgia Institute of Technology 18 5,000 AUSTRALIA University of Technology Sydney 19 5,000 GERMANY Technical University of Munich 20 5,000 CHINA University of Science & Technology of China 21 5,000 UNITED KINGDOM University College London 22 5,000 USA Cornell University 23 5,000 UNITED KINGDOM Imperial College London 24 5,000 CHINA University of Electronic Science & Technology of China 25 5,000 USA University of North Carolina Chapel Hill 26 5,000 CHINA Beihang University 27 5,000 CHINA Zhejiang University 28 5,000 CHINA Huazhong University of Science & Technology 29 5,000 USA University of Southern California
    [Show full text]